Skip to main content
SpringerLink
Log in

Hepatic Veno-Occlusive Disease

  • Chapter
Hematopoietic Stem Cell Transplantation

Part of the book series: Contemporary Hematology ((CH))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors. Hepatology. 1984;4:116–122.

    Article  PubMed  CAS  Google Scholar 

  2. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood. 1995;85:3005–3020.

    PubMed  CAS  Google Scholar 

  3. Richardson PG, Guinan EC. The pathology, diagnosis and treatment of hepatic veno-occlusive disease: current status and novel approaches. British Journal of Haematology. 1999;107:485–693.

    Article  PubMed  CAS  Google Scholar 

  4. Lee JL, Gooley T, Bensinger W, Schiffman K, McDonald GB. Venocclusive disease of the liver after high-dose chemotherapy with alkylating agents: incidence, outcome and risk factors. Hepatology. 1997;26:149A.

    Article  Google Scholar 

  5. Carreras E, Bertz H, Arcese W et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood. 1998;92:3599–3604.

    PubMed  CAS  Google Scholar 

  6. McDonald GB. Venocclusive disease of the liver following marrow transplantation. Marrow Transplantation Reviews. 1993;3:49–56.

    Google Scholar 

  7. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Int Med. 1993;118:255–267.

    PubMed  CAS  Google Scholar 

  8. Holler E, Kolbe HJ, Moller A et al. Increased serum levels of TNFa precede major complications of bone marrow transplantation. Blood. 1990;75:1011–1016.

    PubMed  CAS  Google Scholar 

  9. Krenger W, Hill GR, Ferrara JLM. Cytokine cascades in acute graft-versus-host disease. Transplantation. 1997;64:553–558.

    Article  PubMed  CAS  Google Scholar 

  10. Baglin TP. Veno-occlusive disease of the liver complicating bone marrow transplantation. Bone Marrow Transplant. 1994;13:1–4.

    PubMed  CAS  Google Scholar 

  11. Richardson P, Murakami C, Jin Z et al. Multi-institutional use of defibrotide in 88 patients post stem cell transplant with severe veno-occlusive disease and multisystem organ failure; response without significant toxicity in a high risk population and Factors Predictive of Outcome. Blood. 2002;100:4337–4343.

    Article  PubMed  CAS  Google Scholar 

  12. Richardson PG, Elias AD, Krishnan A et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998;92:737–744.

    PubMed  CAS  Google Scholar 

  13. Shirai M, Nagashima K, Iwasaki S, Mori W. A light and scanning electron microscopic study of hepatic veno-occlusive disease. Acta Pathol Jpn. 1987;37:1961–1971.

    PubMed  CAS  Google Scholar 

  14. Shulman HM, McDonald GB, Matthews D et al. An analysis of hepatic venoc-clusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology. 1980;79:1178–1191.

    PubMed  CAS  Google Scholar 

  15. Shulman HM, Fisher LB, Schoch HG, Kenne KW, McDonald GB. Venoocclusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology. 1994;19:1171–1180.

    Article  PubMed  CAS  Google Scholar 

  16. Shulman HM, Gown AM, Nugent DJ. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol. 1987;127:549–558.

    PubMed  CAS  Google Scholar 

  17. DeLeve L, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis. 2002;22:27–42.

    Article  PubMed  Google Scholar 

  18. Wadleigh M, Richardson P, Zahrieh D et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102:1578–1582.

    Article  PubMed  CAS  Google Scholar 

  19. McKoy JM, Angelotta C, Bennett CL et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2006.

    Google Scholar 

  20. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002;99:2310–2314.

    Article  PubMed  CAS  Google Scholar 

  21. DeLeve LD. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology. 1996;24:830–837.

    Article  PubMed  CAS  Google Scholar 

  22. Kumar S, DeLeve LD, Kamath PS, Tefferi A. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc. 2003;78:589–598.

    Article  PubMed  Google Scholar 

  23. Allen JR, Carstens LA, Katagiri GJ. Hepatic veins of monkeys with veno-occlusive disease. Sequential ultrastructural changes. Arch Pathol. 1969;87:279–289.

    PubMed  CAS  Google Scholar 

  24. Ridker PN, McDermont WV. Hepatotoxicity due to comfrey herb tea [letter; comment] [see comments]. Am J Med. 1989;87:701.

    Article  PubMed  CAS  Google Scholar 

  25. Traber PG, Chianale J, Gumucio JJ. Physiologic significance and regulation of hepa-tocellular heterogeneity [see comments]. Gastroenterology. 1988;95:1130–1143.

    PubMed  CAS  Google Scholar 

  26. el Mouelhi M, Kauffman FC. Sublobular distribution of transferases and hydro-lases associated with glucuronide, sulfate and glutathione conjugation in human liver. Hepatology. 1986;6:450–456.

    Article  PubMed  CAS  Google Scholar 

  27. Deleve LD. Dacarbazine toxicity in murine liver cells: a model of hepatic endothe-lial injury and glutathione defense. J Pharmacol Exp Ther. 1994;268:1261–1270.

    PubMed  CAS  Google Scholar 

  28. Teicher BA, Crawford JM, Holden SA et al. Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide. Cancer. 1988;62:1275–1281.

    Article  PubMed  CAS  Google Scholar 

  29. Hassan Z, Hellstrom-Lindberg E, Alsadi S, Edgren M, Hagglund H, Hassan M. The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo. Bone Marrow Transplant. 2002;30:141–147.

    Article  PubMed  CAS  Google Scholar 

  30. McDonald GB, Slattery JT, Bouvier ME et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematpoietic stem cell transplantation. Blood. 2003;101:2043–2048.

    Article  PubMed  CAS  Google Scholar 

  31. Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol. 1993;20:18–25.

    PubMed  CAS  Google Scholar 

  32. Hassan M, Oberg G, Bekassy AN et al. Pharmacokinetics of high-dose busul-phan in relation to age and chronopharmacology. Cancer Chemother Pharmacol. 1991;28:130–134.

    Article  PubMed  CAS  Google Scholar 

  33. Schuler U, Schroer S, Kuhnle A et al. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplantation. 1994;14:759–765.

    PubMed  CAS  Google Scholar 

  34. Yeager AM, Wagner JE, Jr., Graham ML, Jones RJ, Santos GW, Grochow LB. Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood. 1992;80:2425–2428.

    PubMed  CAS  Google Scholar 

  35. Clopes A, Sureda A, Sierra J et al. Absence of veno-occlussive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantation with targeted busulfan dosage. Eur J Haematol. 2006;77:1–6.

    Article  PubMed  CAS  Google Scholar 

  36. Lee JH, Choi SJ, Lee JH et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol. 2005;84:321–330.

    Article  PubMed  CAS  Google Scholar 

  37. Tran H, Petropoulos D, Worth L et al. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2004;10:805–812.

    Article  PubMed  CAS  Google Scholar 

  38. Slattery JT, Kalhorn TF, McDonald GB et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol. 1996;14:1484–1494.

    PubMed  CAS  Google Scholar 

  39. DeLeve LD. Glutathione defense in non-parenchymal cells. Semin Liver Dis. 1998;18:403–413.

    Article  PubMed  CAS  Google Scholar 

  40. de Jonge ME, Huitema AD, Beijnen JH, Rodenhuis S. High exposures to bioacti-vated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. Br J Cancer. 2006;94:1226–1230.

    Article  PubMed  CAS  Google Scholar 

  41. Wang X, Kanel GC, DeLeve LD. Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat. Hepatology. 2000;31:428–434.

    Article  PubMed  CAS  Google Scholar 

  42. Ringden O, Remberger M, Lehmann S et al. N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation. Bone Marrow Transplant. 2000;25:993–996.

    Article  PubMed  CAS  Google Scholar 

  43. Catani L, Gugliotta L, Vianelli N et al. Endothelium and bone marrow transplantation. Bone Marrow Transplant. 1996;17:277–280.

    PubMed  CAS  Google Scholar 

  44. Salat C, Holler E, Reinhardt B, et al. Parameters of the fibrinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease. Bone Marrow Transplant. 1994;14:747–750.

    PubMed  CAS  Google Scholar 

  45. Salat C, Holler E, Kolbe HJ et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplant. Blood. 1997;89:2184–2188.

    PubMed  CAS  Google Scholar 

  46. Smith LH, Dixon JD, Stringham JR et al. Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood. 2006;107:132–134.

    Article  PubMed  CAS  Google Scholar 

  47. Sato Y, Asada Y, Hara S et al. Hepatic stellate cells (Ito cells) in veno-occlusive disease of the liver after allogeneic bone marrow transplantation. Histopathology. 1999;34:66–70.

    Article  PubMed  CAS  Google Scholar 

  48. Lee JH, Lee KH, Lee JH et al. Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide. Br J Haematol. 2002;118:1087–1094.

    Article  PubMed  CAS  Google Scholar 

  49. Richardson P, Krishnan A, Wheeler C et al. Elevation of PAI-1 levels in BMT-asso-ciated VOD and changes seen with the use of defibrotide. Blood. 1996;88:458a.

    Google Scholar 

  50. Richardson P, Hoppensteadt D, Elias A et al. Elevation of tissue factor pathway inhibitor [TFPI], thrombomodulin [TM] and plasminogen activator inhibitor-1 [PAI-1] levels in stem cell transplant [SCT]-Associated veno-occlusive disease [VOD] and changes seen with the use of defibrotide [DF]. Blood. 1997;90:219a.

    Google Scholar 

  51. Richardson PG, Hoppensteadt DA, Elias AD et al. Elevation of endothelial stress products and trends seen in patients with severe veno-occlusive disease treated with defibrotide. Thrombosis and Haemostasis. 1999;Supplement:628.

    Google Scholar 

  52. Nurnberger W, Michelmann I, Burdach S, Gobel U. Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications. Ann Hematol. 1998; 76:61–65.

    Article  PubMed  CAS  Google Scholar 

  53. Pihusch M, Wegner H, Goehring P et al. Diagnosis of hepatic veno-occlusive disease by plasminogen activator inhibitor-1 plasma antigen levels: a prospective analysis in 350 allogeneic hematopoietic stem cell recipients. Transplantation. 2005;80:1376–1382.

    Article  PubMed  CAS  Google Scholar 

  54. Bianchi M, Tracey KJ. The role of TNF in complications of marrow transplantation. Marrow Transplantation Reviews. 1993/94;3:57–61.

    Google Scholar 

  55. Scrobohaci ML, Drouet L, Monem-Mansi A et al. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. Thromb Res. 1991;63:509–519.

    Article  PubMed  CAS  Google Scholar 

  56. Ferra C, de Sanjose S, Gallardo D et al. IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation. Haematologica. 1998;83:1082–1087.

    PubMed  CAS  Google Scholar 

  57. Schots R, Kaufman L, Va n Riet I et al. Monitoring of C-reactive protein after allo-geneic bone marrow transplantation identifies patients at risk of severe transplant-related complications and mortality. Bone Marrow Transplant. 1998;22:79–85.

    Article  PubMed  CAS  Google Scholar 

  58. Anscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL. Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med. 1993;328: 1592–1598.

    Article  PubMed  CAS  Google Scholar 

  59. Eltumi M, Trivedi P, Hobbs J et al. Monitoring of veno-occlusive disease after bone marrow transplantation by serum aminopropepide of type III procollagen. Lancet. 1993;342:518–521.

    Article  PubMed  CAS  Google Scholar 

  60. Park YD, Yasui M, Yoshimoto T et al. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplant. 1997;19:915–920.

    Article  PubMed  CAS  Google Scholar 

  61. Pihusch V, Pihusch M, Penovici M, Kolb HJ, Hiller E, Pihusch R. Transforming growth factor beta-1 released from platelets contributes to hypercoagulability in veno-occlusive disease following hematopoetic stem cell transplantation. Thromb Res. 2005;116:233–240.

    Article  PubMed  CAS  Google Scholar 

  62. Rio B, Bauduer F, Arrago JP, Zittoun R. N-terminal peptide of type III procol-lagen: a marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin. Bone Marrow Transplant. 1993;11:471–472.

    PubMed  CAS  Google Scholar 

  63. Eltumi M, Trivedi P, Hobbs JR et al. Monitoring of veno-occlusive disease after bone marrow transplantation by serum aminopropeptide of type III procollagen [see comments]. Lancet. 1993;342:518–521.

    Article  PubMed  CAS  Google Scholar 

  64. Heikinheimo M, Halila R, Fasth A. Serum procollagen type III is an early and sensitive marker for veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Blood. 1994;83:3036–3040.

    PubMed  CAS  Google Scholar 

  65. Collins PW, Gutteridge CN, O'Driscoll A et al. von Willebrand factor as a marker of endothelial cell activation following BMT. Bone Marrow Transplant. 1992;10:499–506.

    PubMed  CAS  Google Scholar 

  66. Park YD, Yoshioka A, Kawa K et al. Impaired activity of plasma von Willebrand factor-cleaving protease may predict the occurrence of hepatic veno-occlusive disease after stem cell transplantation. Bone Marrow Transplant. 2002;29:789–794.

    Article  PubMed  Google Scholar 

  67. Harper PL, Jarvis J, Jennings I, Luddington R, Marcus RE. Changes in the natural anticoagulants following bone marrow transplantation. Bone Marrow Transplant. 1990;5:39–42.

    PubMed  CAS  Google Scholar 

  68. Haire WD, Ruby EI, Gordon BG et al. Multiple organ dysfunction syndrome in bone marrow transplantation. JAMA. 1995;274:1289–1295.

    Article  PubMed  CAS  Google Scholar 

  69. Batsis I, Yannaki E, Kaloyannidis P et al. Veno-occlusive disease prophylaxis with fresh frozen plasma and heparin in bone marrow transplantation. Thromb Res. 2006;118:611–618.

    Article  PubMed  CAS  Google Scholar 

  70. Faioni EM, Krachmalnicoff A, Bearman SI et al. Naturally occuring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver. Blood. 1993;81:3458–3462.

    PubMed  CAS  Google Scholar 

  71. Sudhoff T, Heins M, Sohngen D et al. Plasma levels of D-dimer and circulating endothelial adhesion molecules in veno-occlusive disease of the liver following allogeneic bone marrow transplantation. Eur J Haematol. 1998;60:106–111.

    Article  PubMed  CAS  Google Scholar 

  72. Oh H, Tahara T, Bouvier M, Farrand A, McDonald GB. Plasma thrombopoietin levels in marrow transplant patients with veno-occlusive disease of the liver. Bone Marrow Transplant. 1998;22:675–679.

    Article  PubMed  CAS  Google Scholar 

  73. Nevill TJ, Barnett MJ, Klingemann H-G et al. Regimen-related toxicity of busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. Journal of Clinical Oncology. 1991;9:1224–1232.

    PubMed  CAS  Google Scholar 

  74. Matute-Bello G, McDonald GD, Hinds MS, Schoch HG, Crawford SW. Association of pulmonary function testing abnormalities and severe veno-occlu-sive disease of the liver after marrow transplantation. Bone Marrow Transplant. 1998;21:1125–1130.

    Article  PubMed  CAS  Google Scholar 

  75. Hagglund H, Remberger M, Klaesson S, Lonnqvist B, Ljungman P, Ringden O. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation [see comments]. Blood. 1998;92:4568–4572.

    PubMed  CAS  Google Scholar 

  76. Soiffer R, Dear K, Rabinowe SN, et al. Hepatic dysfunction follwoing T-cell-depleted allogeneic bone marrow transplantation. Transplantation. 1991;52:1014–1019.

    Article  PubMed  CAS  Google Scholar 

  77. Moscardo F, Sanz GF, De la Rubia J. Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34+ positive selection. Bone Marrow Transplant. 2001;27:983–988.

    Article  PubMed  CAS  Google Scholar 

  78. Moscardo F, A. U-I, Sanz GF et al. Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identi-cal sibling allogeneic peripheral blood stem cell transplantation. Exp Hematol. 2003;31:545–550.

    Article  PubMed  Google Scholar 

  79. Ringden O, Ruutu T, Remberger M et al.. A Randomized trial comparing busulfan with total ody irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the nordic bone arrow transplantation group. Blood. 1994;83:2723–2730.

    PubMed  CAS  Google Scholar 

  80. Styler MJ, Crilley P, Biggs J. Hepatic dysfunction following busulfan and cyclo-phosphamide myeloblation: a retrospective, multicenter analysis. Bone Marrow Transplant. 1996;18:171–176.

    PubMed  CAS  Google Scholar 

  81. Rozman C, Carreras E, Qian C et al. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. Bone Marrow Transplant. 1996;17:75–80.

    PubMed  CAS  Google Scholar 

  82. Fisher DC, Vredenburgh JJ, Petros WP et al. Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver. Bone Marrow Transplant. 1998;21:117–122.

    Article  PubMed  CAS  Google Scholar 

  83. Korbling M, Katz RL, Khanna A et al. Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med. 2002;346:738–746.

    Article  PubMed  Google Scholar 

  84. Tack DK, Letendre L, Kamath P, Tefferi A. Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia. Bone Marrow Transplant. 2001;28:895–897.

    Article  PubMed  CAS  Google Scholar 

  85. McDonald GB. Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzmab ozogamicin (mylotarg (r) ). Clin Lymphoma. 2002;2:S35–39.

    Article  Google Scholar 

  86. Arceci RJ, Sande J, Lange B et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood. 2005;106:1183–1188.

    Article  PubMed  CAS  Google Scholar 

  87. Jones RJ, Lee KSK, Beschorner WE et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44:778–783.

    Article  PubMed  CAS  Google Scholar 

  88. Brown BP, Abu-Yousef M, Farner R, LaBrecque D, Gingrich R. Doppler sonog-raphy: a noninvasive method for evaluation of hepatic venocclusive disease. AJR. 1990;154:721–724.

    PubMed  CAS  Google Scholar 

  89. Hosoki T, Kuroda C, Tokunaga K, Marukawa T, Masuike M, Kozuka T. Hepatic venous outflow obstruction: evaluation with pulsed duplex sonography. Radiology. 1989;170:733–737.

    PubMed  CAS  Google Scholar 

  90. Nicolau C, Concepcio B, Carreras E et al. Sonographic diagnosis and hemody-namic correlation in veno-occlusive disease of the liver. J Ultrasound Med. 1993; 12:437–440.

    PubMed  CAS  Google Scholar 

  91. Sonneveld P, Lameris JS, Cornelissen J, Ogilvie A, Lowenberg B. Color-flow imaging sonography of portal and hepatic vein flow to monitor fibrinolytic therapy with r-TPA for veno-occlusive disease following myeloablative treatment. Bone Marrow Transplant. 1998;21:731–734.

    Article  PubMed  CAS  Google Scholar 

  92. van den Bosch MA, van Hoe L. MR imaging findings in two patients with hepatic veno-occlusive disease following bone marrow transplantation [In Process Citation]. Eur Radiol. 2000;10:1290–1293.

    Article  PubMed  Google Scholar 

  93. Carreras E, Granena A, Navasa M et al. Transjugular liver biopsy in BMT. Bone Marrow Transplant. 1993;11:21–26.

    PubMed  CAS  Google Scholar 

  94. Shulman HM, Gooley T, Dudley MD et al. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation. 1995;59:1015–1022.

    Article  PubMed  CAS  Google Scholar 

  95. Bearman SI, Shen D, Hinds MS, Hill H, McDonald GB. A phase 1/2 study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation. Br J Haematol. 1993;84:724–730.

    Article  PubMed  CAS  Google Scholar 

  96. Lee JH, Lee KH, Lee JH et al. Plasminogen activator inhibitor-1 is an independent diagnositic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide. British Journal of Haematology. 2002;118:1087–1094.

    Article  PubMed  CAS  Google Scholar 

  97. Barrett J, Childs R. Non-myeloblative stem cell transplants. British Journal of Haematology. 2000;111:6–17.

    Article  PubMed  CAS  Google Scholar 

  98. Maris M, Sandmaier BM, Maloney DG et al. Non-myeloblative hematopoietic stem cell transplantation. Transfus Clin Biol. 2001;8:231–234.

    Article  PubMed  CAS  Google Scholar 

  99. Tse WT, Beyer W, Pendleton JD, Richardson P, Guinan EC. Genetic polymorphisms in glutathione s-transferase and plasminogen activator inhibitor and risk of veno-occlusive disease (VOD). Blood. 2000;96:390a.

    Google Scholar 

  100. Poonkuzhali S, Vidya S, Shaji RV, Chandy M, Srivastava A. Glutathione S-trans-ferase gene polymorphism and risk of major undergoing allogeneic bone marrow transplantation. Blood. 2001;98:852a.

    Google Scholar 

  101. Bredschneider M, Klein K, Murdter TE et al. Genetic polymorphisms of glutath-ione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation. Clin Pharmacol Ther. 2002;71:479–487.

    Article  PubMed  CAS  Google Scholar 

  102. Ritter CA, Sperker B, Grube M, Dressel D, Kunert-Keil C, Kroemer HK. Overexpression of glutathione S-transferase A1-1 in ECV 304 cells protects against busulfan mediated G2-arrest and induces tissue factor expression. Br J Pharmacol. 2002;137:1100–1106.

    Article  PubMed  CAS  Google Scholar 

  103. Haire WD, Cavet J, Pavletic SZ, Tarantolo SR, Norden J, Middleton PG. Tumor necrosis factor d3 allele predicts for organ dysfunction after allogeneic blood stem cell transplantation (ABSCT). Blood. 2000;96:584a.

    Google Scholar 

  104. Ohashi K, Tanabe J, Watanabe R et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol. 2000;64:32–38.

    Article  PubMed  CAS  Google Scholar 

  105. Essell JH, Schroeder MT, Harman GS et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:975–981.

    PubMed  CAS  Google Scholar 

  106. Ruutu T, Eriksson B, Remes K et al. Ursodiol prevention of hepatic complications in allogeneic stem cell transplantation: results of a prospective, randomized, placebo-controlled trial. (Abstract). Bone Marrow Transplant. 1999; 23:756.

    Google Scholar 

  107. Ruutu T, Eriksson B, Remes K et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood. 2002;100:1977–1983.

    Article  PubMed  CAS  Google Scholar 

  108. Tay J, Tinmouth A, Fergusson D, Huebsch L, Allan DS. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:206–217.

    Article  PubMed  CAS  Google Scholar 

  109. Jonas CR, Puckett AB, Jones DP et al. Plasma antioxidant status after high-dose chemotherapy: a randomized trial of parenteral nutrition in bone marrow transplantation patients. Am J Clin Nutr. 2000;72:181–189.

    PubMed  CAS  Google Scholar 

  110. Goringe AP, Brown S, O'Callaghan U et al. Glutamine and vitamin E in the treatment of hepatic veno-occlusive disease following high-dose chemotherapy. Bone Marrow Transplant. 1998;21:829–832.

    Article  PubMed  CAS  Google Scholar 

  111. Khoury H, Adkins D, Trinkaus K et al. Treatment of hepatic veno-occlusive disease with high dose corticosteroids: an update on 28 stem cell transplant recipients. Blood. 1998;92:1132 (abstract).

    Google Scholar 

  112. Ferra C, Sanjose S, Lastra CF et al. Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications. Bone Marrow Transplant. 1997;20:1075–1080.

    Article  PubMed  CAS  Google Scholar 

  113. Clift RA, Bianco JA, Appelbaum FR et al. A randomized controlled trial of pen-toxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood. 1993;82:2025–2030.

    PubMed  CAS  Google Scholar 

  114. Attal M, Huguet F, Rubie H. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood. 1992;79:2834–2840.

    PubMed  CAS  Google Scholar 

  115. Bearman SI, Hinds MS, Wolford JL. A pilot study of continuous infusion heparin for the prevention of hepatic veno-occlusive disease after bone marrow transplantation. Bone Marrow Transplant. 1990;5:407–411.

    PubMed  CAS  Google Scholar 

  116. Marsa-Vila L, Gorin NC, Laporte JP. Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation. European Journal of Haematology. 1991;47:346–352.

    Article  PubMed  CAS  Google Scholar 

  117. Budinger MD, Bouvier M, Shah A, McDonald GB. Results of a phase 1 trial of anti-thrombin III as prophylaxis in bone marrow transplant patients at risk for venocclusive disease. Blood. 1996;88:172a (abstract).

    Google Scholar 

  118. Lee JH, Lee KH, Choi JS et al. Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment. J Korean Med Sci. 1996;11:118–126.

    PubMed  CAS  Google Scholar 

  119. Or R, Nagler A, Shpilberg O et al. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation. 1996;61:1067–1071.

    Article  PubMed  CAS  Google Scholar 

  120. Forrest DL, Thompson K, Dorcas VG, Couban SH, Pierce R. Low molecular weight heparin for the prevention of veno-occlusive disease (VOD) after hemat-opoietic stem cell transplantation: a prospective phase II study. Bone Marrow Transplant. 2003;31:1143–1149.

    Article  PubMed  CAS  Google Scholar 

  121. Simon M, Hahn T, Ford LA et al. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin. Bone Marrow Transplant. 2001;27:627–633.

    Article  PubMed  CAS  Google Scholar 

  122. Vaughan DE, Plavin SR, Schafer AI. PGE1 accelerates thrombolysis by tissue plasminogen activator. Blood. 1989;73:1213–1217.

    PubMed  CAS  Google Scholar 

  123. Gluckman E, Jolivet I, Scrobohaci ML. Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. British Journal of Haematology. 1990;74:277–281.

    Article  PubMed  CAS  Google Scholar 

  124. Schriber JR, Milk BJ, Baer MR. A randomized phase II trial comparing heparin (Hep) +/- prostaglandin E1 (PG) to prevent hepatotoxicity (HT) following bone marrow transplantation (BMT): preliminary results. Blood. 1996;88:1642.

    Google Scholar 

  125. Chalandon Y, Roosnek E, Mermillod B et al. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2004;10:347–354.

    Article  PubMed  CAS  Google Scholar 

  126. Bearman SI, Shuhart MC, Hinds MS, McDonald GB. Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation. Blood. 1992;80:2458–2462.

    PubMed  CAS  Google Scholar 

  127. Leahey AM, Bunin NJ. Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients. Bone Marrow Transplant. 1996;17:1101–1104.

    PubMed  CAS  Google Scholar 

  128. Litzow MR, Repoussis PD, Schroeder G et al. Veno-occlusive disease of the liver after blood and marrow transplantation: analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activator. Leuk Lymphoma. 2002;43:2099–2107.

    Article  PubMed  Google Scholar 

  129. Bearman SI, Lee JL, Baron AE, McDonald GB. Treatment of hepatic venocclu-sive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood. 1997;89:1501–1506.

    PubMed  CAS  Google Scholar 

  130. Haire WD, Stephens LC, Ruby EI. Antithrombin III (AT3) treatment of organ dysfunction during bone marrow transplantation (BMT) - results of a pilot study. Blood. 1996;88:458a (abstract).

    Google Scholar 

  131. Strasser SI, McDonald GB. Gastrointestinal and hepatic complications. In: Forman SJ, Blume KG, Thomas ED, eds. Hematopoietic Cell Transplantation (2nd Edition): Blackwell Scientific Publication; 1998.

    Google Scholar 

  132. Ibrahim RB, Peres E, Dansey R, Abidi MH, Abella EM, Klein J. Anti-thrombin III in the management of hematopoietic stem-cell transplantation-associated tox-icity. Ann Pharmacother. 2004;38:1053–1059.

    Article  PubMed  CAS  Google Scholar 

  133. Haire WD, Ruby EI, Stephens LC et al. A prospective randomized double-blind trial of antithrombin III concentrate in the treatment of multiple-organ dysfunction syndrome during hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 1998;4:142–150.

    PubMed  CAS  Google Scholar 

  134. Morris JD, Harris RE, Hashmi R et al. Antithrombin - III for the treatment of chemotherapy - induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant. 1997;20:871– 878.

    Article  PubMed  CAS  Google Scholar 

  135. Ibrahim A, Pico JL, Maraninchi D et al. Hepatic veno-occlusive disease following bone marrow transplantation treated by prostaglandin E1. Bone Marrow Transplant (Suppl). 1991;7:53.

    PubMed  Google Scholar 

  136. Bianchi G, Barone D, Lanzarotti E et al. Defibrotide, a single-stranded polyde-oxyribonucleotide acting as an adenosine receptor agonist. European Journal of Pharmacology. 1993;238:327–334.

    Article  PubMed  CAS  Google Scholar 

  137. Eissner G, Multhoff G, Gerbitz A et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood. 2002;100:334–340.

    Article  PubMed  CAS  Google Scholar 

  138. Bracht F, Schror K. Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro. Biochemical and Biophysical Research Communications. 1994;200:933–936.

    Article  PubMed  CAS  Google Scholar 

  139. Kornblum N, Ayyanar K, Benimetskaya L, Richardson P, Iacobelli M, Stein CA. Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucle-otides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of action. Oligonucleotides. 2006;16:105–114.

    Article  PubMed  CAS  Google Scholar 

  140. Berti F, Rossoni G, Biasi G, Buschi A, Mandelli V. Defibrotide by enhancing prostacyclin generation prevents endothelin-I induced contraction in human saphenous veins. Prostaglandins. 1990;40:337–350.

    Article  PubMed  CAS  Google Scholar 

  141. Coccheri S, Biagi G. Defibrotide. Cardiovascular Drug Review. 1991;9:172–196.

    Article  CAS  Google Scholar 

  142. Fareed J. Modulation of endothelium by heparin and related polyelectrolytes. In: Nicolaides A, Novo S, eds. Advances in Vascular Pathology 1997. Amsterdam: Elsevier Science B.V.; 1997.

    Google Scholar 

  143. Zhou Q, Chu X, Ruan C. Defibrotide stimulates expression of thrombomodulin in human endothelial cells. Thrombosis and Hemostasis. 1994;71:507–510.

    CAS  Google Scholar 

  144. Palmer KJ, Goa KL. Defibrotide: A review of its pharmacodynamic and pharmaco-kinetic properties, and therapeutic use in vascular disorders. Drugs. 1993;45:259–294.

    Article  Google Scholar 

  145. Coccheri S, Biagi G, Legnani C, Bianchini B, Grauso F. Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man. Eur J Clin Pharmacol. 1988;35:151–156.

    Article  PubMed  CAS  Google Scholar 

  146. Ulutin ON. Antithrombotic effect and clinical potential of defibrotide. Sem Thrombosis and Hemostasis. 1993;19:186–191.

    Google Scholar 

  147. Jamieson A, Alcock P, Tuffin DP. The action of polyanionic agents defibrotide and pentosan sulphate on fibrinolytic activity in the laboratory rat. Fibrinolysis. 1996;10:27–35.

    Article  Google Scholar 

  148. Bonomini V, Vangelista A, Frasca GM. A new antithrombotic agent in the treatment of acute renal failure due to hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura. Nephron. 1984 (letter);37:144.

    Article  PubMed  CAS  Google Scholar 

  149. Viola F, Marubini S, Coccheri G, Nenci G. Improvement of walking distance by defibrotide in patients with intermittent claudication: results of a randomized, placebo-controlled study (the DICLIS study). Thrombosis and Haemostasis. 2000;83:672–677.

    Google Scholar 

  150. Falanga A, Marchetti M, Vignoli A, Barbui T. Defibrotide (DF) modulates tissue factor expression by microvascular endothelial cells. Blood. 1999;94:146a.

    Google Scholar 

  151. Falanga A, Marchetti M, Vignoli A, Barbui T. Impact of defibrotide on the fibri-nolytic and procoagulant properties of endothelial cell macro- and micro-vessels. Blood. 2000;96:53a.

    Google Scholar 

  152. Abecasis M, Ferreira I, Guimaraes A, Machado A. Defibrotide as salvage therapy for hepatic veno-occlusive disease (VOD). Bone Marrow Transplant. 1999;23:749 (abstract).

    Google Scholar 

  153. Salat C, Pihusch R, Fries S et al. Successful treatment of veno-occlsive disease with defibrotide - a report of two cases. Bone Marrow Transplant. 1999;23:757 (abstract).

    Google Scholar 

  154. Zinke W, Neumeister P, Linkesch W. Defibrotide- an approach in the treatment of severe veno-occlusive disease? Bone Marrow Transplant. 1999;23:760 (abstract).

    Google Scholar 

  155. Jenner MJ, Micallef IN, Rohatiner AZ, Kelsey SM, Newland AC, Cavenagh JD. Successful therapy of transplant-associated veno-occlusive disease with a combination of tissue plasminogen activator and defibrotide. [In Process Citation]. Med Oncol. 2000;17:333–336.

    Article  PubMed  CAS  Google Scholar 

  156. Chopra R, Eaton JD, Grassi A et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. British Journal of Haematology. 2000;111:1122–1129.

    Article  PubMed  CAS  Google Scholar 

  157. Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, McDonald GB. Venoocclusive disease of the liver: Development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol. 1993;11:1729–1736.

    Google Scholar 

  158. Richardson P, Soiffer R, Antin JH et al. Defibrotide (DF) for the Treatment of Severe Veno-Occlusive Disease (sVOD) and Multi-Organ Failure (MOF) Post SCT: Final Results of a Multi-Center, Randomized, Dose-Finding Trial. Abstract #43. Blood. 2006;108.

    Google Scholar 

  159. Bulley SR, Strahm B, Doyle J, Dupuis LL. Defibrotide for the treatment of hepatic veno-occlusive disease in children. Pediatr Blood Cancer. 2006.

    Google Scholar 

  160. Corbacioglu S, Greil J, Peters C et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant. 2004;33:189–195.

    Article  PubMed  CAS  Google Scholar 

  161. Schlitt HJ, Tischler HJ, Ringe B et al. Allogeneic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantation - clinical and immuno-logical considerations. Bone Marrow Transplant. 1995;16:473–478.

    PubMed  CAS  Google Scholar 

  162. Fried MW, Connaghan DG, Sharma S et al. Trans jugular intrahepatic protosys-temic shunt for the management of severe venocclusive disease following bone marrow transplantation. Hepatology. 1996;24:588–591.

    Article  PubMed  CAS  Google Scholar 

  163. Smith FO, Johnson MS, Scherer LR et al. Transjugular intrahepatic portosystemic shunting (TIPS) for the treatment of severe hepatic veno-occlusive disease. Bone Marrow Transplant. 1996;18:643–646.

    PubMed  CAS  Google Scholar 

  164. Alvarez R, Banares R, Casariego J et al. Percutaneous intrahepatic portosystemic shunting in the treatment of veno-occlusive disease of the liver after bone marrow transplantation. Gastroenterol Hepatol. 2000;23:177–180.

    PubMed  CAS  Google Scholar 

  165. Tefferi A, Kumar S, Wolf R et al. Charcoal hemofiltration for hepatic veno-occulsive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;28:997–999.

    Article  PubMed  CAS  Google Scholar 

  166. Baglin TP, Harper P, Marcus RE. Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rt-PA). Bone Marrow Transplant. 1990;5:439–441.

    PubMed  CAS  Google Scholar 

  167. Laporte JP, Lesage S, Tilleul P, Najman A, Gorin NC. Alteplase for hepatic veno-occlusive disease complicating bone-marrow transplantation [letter] [see comments]. Lancet. 1992;339:1057.

    Article  PubMed  CAS  Google Scholar 

  168. Rosti G, Bandini G, Belardinelli A et al. Alteplase for hepatic veno-occlusive disease after bone-marrow transplantation [letter; comment] [see comments]. Lancet. 1992;339:1481–1482.

    Article  PubMed  CAS  Google Scholar 

  169. Ringden O, Wennberg L, Ericzon BG et al. Alteplase for hepatic veno-occlu-sive disease after bone marrow transplantation [letter; comment]. Lancet. 1992;340:546–547.

    Article  PubMed  CAS  Google Scholar 

  170. Feldman L, Gabai E, Milovic V, Jaimovich G. Recombinant tissue plaminogen activator (rTPA) for hepatic veno-occlusive disease after allogeneic BMT in a pediatric patient. 1995;16:727–731.

    CAS  Google Scholar 

  171. Goldberg SL, Shubert J, Rao AK, Redei I, Klumpp TR, Mangan KF. Treatment of hepatic veno-occlusive disease with low-dose tissue plasminogen activator: impact on coagulation profile. Bone Marrow Transplant. 1996;18:633–636.

    PubMed  CAS  Google Scholar 

  172. Higashigawa M, Watanabe M, Nishihara H et al. Successful treatment of an infant with veno-occlusive disease developed after allogeneic bone marrow transplantation by tissue plasminogen activator, heparin and prostaglandin E1. Leuk Res. 1995;19:477–480.

    Article  PubMed  CAS  Google Scholar 

  173. Hagglund H, Ringden O, Ljungman P. No beneficial effects, but severe side effects caused by recombinant human tissue plasminogen activator for treatment of hepatic veno-occlusive disease after allogeneic bone marrow transplantation. Transplantation. 1995;27:3535.

    CAS  Google Scholar 

  174. Yu LC, Malkani I, Regueira O, Ode DL, Warrier RP. Recombinant tissue plas-minogen activator (rt-PA) for veno-occlusive liver disease in pediatric autologous bone marrow transplant patients. Am J Hematol. 1994;46:194–198.

    Article  PubMed  CAS  Google Scholar 

  175. Schriber J, Milk B, Shaw D et al. Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation. Bone Marrow Transplant. 1999;24:1311–1314.

    Article  PubMed  CAS  Google Scholar 

  176. Kulkarni S, Rodriguez M, Lafuente A et al. Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD). Bone Marrow Transplant. 1999;23:803–807.

    Article  PubMed  CAS  Google Scholar 

  177. Coppell JA, Richardson PG, Martin PL et al. Incidence of hepatic venoocclusive disease following stem cell transplatation: Systematic review of literature from 1979–2007. BMT 208; 41(Supp 1): S91

    Google Scholar 

  178. Dignan D, Gujral D, Ethell M, et al. Prophylactic defibrotide in allogeneic stem cell transplatation: Minimal morbidity and zero mortality from veno-occlusive disease. BMT 2007;40: 79–82.

    CAS  Google Scholar 

  179. Qureshi A, Marshall L, Lancaster D. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogenenic stem cell transplatation in children. Pediatr Blood Cancer 2008;50:831–2.

    Article  PubMed  Google Scholar 

  180. Corbacioglu S. Update on the Phase II/III study of the incidence and outcome of VOD with the prophylactic use of defibrotide in paediatric stem cell transplatation (VOD-DF Study). BMT 2008; 41 (Supp 2):S34.

    Google Scholar 

  181. Richardson PG, Kaman N, Tomblyn M, et al. A Phase 3 Randomized, Historically-Controlled Clinical Trial Investigating the Use of Defibrotide in the Treatment of Severe Veno-Occlusive Disease Post-SCT: A Novel Approach to the Validation of a Promising New Drug for the Treatment of a Life Threatening Disease. Blood 2007; 110:614.

    Article  CAS  Google Scholar 

  182. Komblum N, Ayyanar K, Benimetskaya L, Richardson P, lacobelli M, Stei CA. Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucle-otides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of action. Oligonucleotides. 2006 Spring; 16(1): 105–14.

    Article  Google Scholar 

Download references

Acknowledgments

The authors gratefully acknowledge the assistance of Cartin Conaut and Amy Potenza in the preparation of this manuscript. The photomicrographs were kindly provided by Howard Shulman, M.D.

Author information

Authors and Affiliations

  1. Department of Adult Oncology,Dana - Farber Cancer Institute, Harvard Medical School, Boston, MA

    Erica Linden

  2. Division of Hematology Malignancies, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

    Paul Richardson

Authors
  1. Erica Linden
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Richardson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Hematologic Malignancies, Dana-Farber Cancer Institute, 44 Binney Street, DFCI D1B30, Boston, MA, 02115, USA

    Robert J. Soiffer MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Linden, E., Richardson, P. (2008). Hepatic Veno-Occlusive Disease. In: Soiffer, R.J. (eds) Hematopoietic Stem Cell Transplantation. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-438-4_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-438-4_21

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-05-3

  • Online ISBN: 978-1-59745-438-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation